Following the science to improve patient outcomes

Our approach

For 40 years, AstraZeneca has pushed the boundaries of science in respiratory disease. Starting with our first bronchodilator, Bricanyl, through to our current marketed products, including Pulmicort, Symbicort and Duaklir Genuair, AstraZeneca scientists continue to transform disease management and patient outcomes in asthma and chronic obstructive pulmonary disease (COPD).

But our job is not yet done. We continue to follow the science by developing targeted inhaled and biologic therapies, unique drug combinations, and devices to ensure the right treatments for the right patients.

Our focus on unmet medical needs

Improving patient outcomes with tailored therapies, devices, and support tools

  • Global burden of respiratory diseases

    Raising awareness of the ongoing unmet medical need in asthma, COPD and idiopathic pulmonary fibrosis (IPF)

  • Inhaled therapies and novel combinations

    Optimising our portfolio of inhaled medicines to improve choice and outcomes for patients across the disease spectrum

  • Targeted biologic therapies

    Using new scientific insights about the biology of respiratory diseases and patient phenotypes to create targeted biologic therapies

What we are working on

Our pipeline

Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.

Phase 3/Reg.* refers to assets that are in Phase 3 or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets.

Respiratory, Inflammation and Autoimmunity (as at 28 July 2016)

Phase 1

Phase 1

  • AZD1419 asthma
  • AZD5634 cystic fibrosis
  • AZD7986 COPD
  • AZD8871 COPD
  • AZD9567 rheumatoid arthritis
  • MEDI0700 systemic lupus erythematosus
  • MEDI4920 primary Sjögren’s syndrome
  • MEDI5872 SLE
  • MEDI9314 atopic dermatitis
  • anifrolumab systemic lupus erythematosus (subcutaneous)
  • lesinurad+allopurinol FDC chronic treatment of hyperuricemia in patients with gout

Phase 2

Phase 2

  • AZD7594 asthma/COPD
  • AZD7624 COPD
  • AZD9412 asthma/COPD
  • MEDI2070 Crohn’s disease
  • PT010 asthma
  • abediterol asthma/COPD
  • anifrolumab lupus nephritis
  • inebilizumab neuromyelitis optica
  • mavrilimumab rheumatoid arthritis
  • tezepelumab asthma/atopic dermatitis
  • tralokinumab atopic dermatitis
  • verinurad chronic treatment of hyperuricemia in patients with gout

Phase 3/Reg.*

Phase 3/Reg.*

  • Bevespi Aerosphere (PT003) GFF PINNACLE COPD
  • PT010 COPD
  • Zurampic (lesinurad) CLEAR 1,2 CRYSTAL chronic treatment of hyperuricemia in patients with gout
  • anifrolumab TULIP systemic lupus erythematosus
  • benralizumab CALIMA SIROCCO ZONDA BISE BORA GREGALE severe asthma
  • brodalumab AMAGINE-1,2,3 psoriasis
  • tralokinumab STRATOS 1,2 TROPOS MESOS severe asthma

LCM Projects

LCM Projects

  • Duaklir Genuair COPD
  • Symbicort breath actuated Inhaler asthma/COPD
  • Symbicort SYGMA as-needed use in mild asthma

Our medicines

Please note that the products mentioned may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries. Country specific information is available from your local AstraZeneca company.

  • Accolate, Accoleit, Vanticon zafirlukast
  • Bricanyl Respules terbutaline
  • Bricanyl Turbuhaler terbutaline in a dry powder inhaler
  • Daliresp/Daxas roflumilast
  • Duaklir Genuair aclidinium/formoterol
  • Eklira Genuair/Tudorza/Bretaris aclidinium, a LAMA
  • Oxis Turbuhaler Oxis Turbuhaler
  • Pulmicort Turbuhaler budesonide
  • Pulmicort Respules budesonide inhalation suspension
  • Rhinocort budesonide
  • Symbicort pMDI budesonide/formoterol
  • Symbicort Turbuhaler budesonide/formoterol

New approaches in the treatment of asthma

Targeting the immune system to try and restore the balance in asthma patients

Read story


Commitment to science

Our commitment to science is reflected in our track record of publications. Here are a few recent examples of high impact and high quality publications co-authored by AstraZeneca and/or MedImmune scientists.

IL-33 drives airway hyper-responsiveness through IL-13-mediated mast cell: airway smooth muscle crosstalk

May 2015

IL-33 drives airway hyper-responsiveness through IL-13-mediated mast cell: airway smooth muscle crosstalk

AstraZeneca/MedImunne AUTHOR
Richard May (MedImmune)


Page Atlas ID: 971713.011
Date of next review: April 2017